Wai Yuen Tong Medicine Holdings Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Ching Ho Tang
Chief executive officer
HK$23.6m
Total compensation
CEO salary percentage | 44.6% |
CEO tenure | 6.6yrs |
CEO ownership | n/a |
Management average tenure | 3.5yrs |
Board average tenure | 5.2yrs |
Recent management updates
Recent updates
Wai Yuen Tong Medicine Holdings Limited's (HKG:897) Share Price Boosted 51% But Its Business Prospects Need A Lift Too
Jul 26Investors Give Wai Yuen Tong Medicine Holdings Limited (HKG:897) Shares A 46% Hiding
Mar 11The Strong Earnings Posted By Wai Yuen Tong Medicine Holdings (HKG:897) Are A Good Indication Of The Strength Of The Business
Dec 28Is Wai Yuen Tong Medicine Holdings (HKG:897) A Risky Investment?
Jul 11Wai Yuen Tong Medicine Holdings (HKG:897) Takes On Some Risk With Its Use Of Debt
Jul 05Is Wai Yuen Tong Medicine Holdings (HKG:897) A Risky Investment?
Mar 08Increases to Wai Yuen Tong Medicine Holdings Limited's (HKG:897) CEO Compensation Might Cool off for now
Aug 18Health Check: How Prudently Does Wai Yuen Tong Medicine Holdings (HKG:897) Use Debt?
Mar 17Wai Yuen Tong Medicine Holdings' (HKG:897) Shareholders Are Down 75% On Their Shares
Jan 22Health Check: How Prudently Does Wai Yuen Tong Medicine Holdings (HKG:897) Use Debt?
Dec 16CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Mar 31 2024 | HK$24m | HK$11m | -HK$27m |
Sep 30 2023 | n/a | n/a | HK$36m |
Jun 30 2023 | n/a | n/a | HK$8m |
Mar 31 2023 | HK$16m | HK$15m | -HK$16m |
Dec 31 2022 | n/a | n/a | -HK$98m |
Sep 30 2022 | n/a | n/a | -HK$176m |
Jun 30 2022 | n/a | n/a | -HK$143m |
Mar 31 2022 | HK$9m | HK$8m | -HK$109m |
Dec 31 2021 | n/a | n/a | -HK$122m |
Sep 30 2021 | n/a | n/a | -HK$135m |
Jun 30 2021 | n/a | n/a | -HK$255m |
Mar 31 2021 | HK$8m | HK$8m | -HK$376m |
Dec 31 2020 | n/a | n/a | -HK$98m |
Sep 30 2020 | n/a | n/a | HK$179m |
Jun 30 2020 | n/a | n/a | HK$309m |
Mar 31 2020 | HK$15m | HK$12m | HK$439m |
Dec 31 2019 | n/a | n/a | HK$253m |
Sep 30 2019 | n/a | n/a | HK$66m |
Jun 30 2019 | n/a | n/a | HK$71m |
Mar 31 2019 | HK$14m | HK$12m | HK$75m |
Dec 31 2018 | n/a | n/a | HK$20m |
Sep 30 2018 | n/a | n/a | -HK$35m |
Jun 30 2018 | n/a | n/a | -HK$75m |
Mar 31 2018 | HK$13m | HK$12m | -HK$116m |
Compensation vs Market: Ching Ho's total compensation ($USD3.03M) is above average for companies of similar size in the Hong Kong market ($USD233.82K).
Compensation vs Earnings: Ching Ho's compensation has increased whilst the company is unprofitable.
CEO
Ching Ho Tang (62 yo)
6.6yrs
Tenure
HK$23,551,000
Compensation
Mr. Ching Ho Tang, GBS, SBS, JP is Chairman of China Agri-Products Exchange Limited since February 8, 2021 and re-designated as its Executive Director since October 01, 2022. Mr. Tang Co-founded Wang On Gr...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Executive Chairman & MD | 6.6yrs | HK$23.55m | no data | |
Executive Director | 6.6yrs | HK$2.20m | no data | |
Assistant GM of Purchasing Processing & Executive Director | 3.8yrs | HK$909.00k | no data | |
Financial Controller | 2.8yrs | no data | no data | |
Head of Factory Operations | 3.2yrs | no data | no data | |
Company Secretary | less than a year | no data | no data |
3.5yrs
Average Tenure
55yo
Average Age
Experienced Management: 897's management team is considered experienced (3.5 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Executive Chairman & MD | 23.3yrs | HK$23.55m | no data | |
Executive Director | 6.6yrs | HK$2.20m | no data | |
Assistant GM of Purchasing Processing & Executive Director | 3.8yrs | HK$909.00k | no data | |
Independent Non-Executive Director | 9.7yrs | HK$204.00k | no data | |
Independent Non-Executive Director | less than a year | HK$45.00k | no data | |
Independent Non-Executive Director | less than a year | HK$45.00k | no data |
5.2yrs
Average Tenure
61.5yo
Average Age
Experienced Board: 897's board of directors are considered experienced (5.2 years average tenure).